Multiple system atrophy (MSA) is a rare, rapidly progressing neurodegenerative disease characterized by poor balance and motor coordination due to the loss of cells in various areas of the nervous system. The symptoms of MSA are similar to those of Parkinson’s disease but tend to progress more quickly, often leading to disability within 5-10 years from the onset. There is currently no cure for MSA though certain medication and therapies can help manage symptoms. The need for effective treatments of MSA is increasing as prevalence of neurodegenerative diseases rise.
The global MSA market is estimated to be valued at US$ 137.3 Mn in 2024 and is expected to exhibit a CAGR of 4.4% over the forecast period 2024-2031.
Key Takeaways
Key players: Key players operating in the MSA market are Chelsea Therapeutics International, Ltd., Biohaven Pharmaceuticals, Inc., Sumitomo Dainippon Pharma Co., Ltd., AstraZeneca plc, Theravance Biopharma, Inc. and Among Others.
Key opportunities: Increasing research funding for developing effectives treatments, growing prevalence of neurodegenerative diseases, and rising awareness are expected to create lucrative growth opportunities in the global MSA market over the forecast period.
Global expansion: Leading market players are increasingly focusing on expansion strategies across high potential markets such as North America, Europe, Asia Pacific and rest of the world through strategic collaborations and partnerships to strengthen their market presence.
Market drivers: The rising prevalence of neurodegenerative diseases primarily due to rapidly aging population is a major market driver. According to estimates, neurodegenerative diseases already affect millions around the world and are expected to become more widespread owing to increasing life expectancy. This is expected to significantly fuel the demand for effective treatments and diagnosis of MSA.
PEST Analysis
Political: The governments of major markets are increasingly focusing on rare and orphan diseases by providing research grants and special policy incentives to boost research and development for Multiple System Atrophy (MSA).
Economic: Development of effective treatments can help reduce healthcare costs associated with long-term management and hospitalization of MSA patients. Higher R&D investments from pharmaceutical companies are driven by potential of profitable returns from sales of novel drugs owing to orphan drug status benefits.
Social: Growing public awareness and patient support groups are driving research efforts to find effective treatments for rare neurodegenerative conditions like MSA.
Technological: Advancements in biomarkers, gene sequencing and imaging technologies are helping researchers better understand disease etiology and progression, aiding drug development process with improved target selection and clinical trial end-points.
The geographical regions where the Multiple System Atrophy (MSA) market in terms of value is most concentrated currently include the United States, Japan, Germany, France and United Kingdom. This is because these countries have higher diagnosed patient populations, adequate healthcare budgets, strong reimbursement policies and presence of key market players. The Asia Pacific region, especially countries like China and South Korea, represents the fastest growing regional market owing to rising healthcare investments, growing medical needs of aging populations and expansion activities of leading pharmaceutical companies in these emerging economies.
The North American region, primarily the United States, represents the largest geographical market for Multiple System Atrophy currently. This is due to factors like large population size and higher disease diagnosis rates in the country, strong healthcare infrastructure and medical reimbursement systems, and presence of leading market players. The United States also has a conducive regulatory environment for orphan drug development through incentives like tax credits, market exclusivity benefits and research grants, boosting R&D activities.
What Are The Key Data Covered In This Multiple System Atrophy (MSA) Market Report?
:- Market CAGR throughout the predicted period
:- Comprehensive information on the aspects that will drive the Multiple System Atrophy (MSA) ‘s growth between 2024 and 2031.
:- Accurate calculation of the size of the Multiple System Atrophy (MSA) and its contribution to the market, with emphasis on the parent market
:- Realistic forecasts of future trends and changes in consumer behaviour
:- Multiple System Atrophy (MSA) Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa
:- A complete examination of the market’s competitive landscape, as well as extensive information on vendors
:- Detailed examination of the factors that will impede the expansion of Multiple System Atrophy (MSA) vendors
FAQ’s
Q.1 What are the main factors influencing the Multiple System Atrophy (MSA) ?
Q.2 Which companies are the major sources in this industry?
Q.3 What are the market’s opportunities, risks, and general structure?
Q.4 Which of the top Multiple System Atrophy (MSA) companies compare in terms of sales, revenue, and prices?
Q.5 Which businesses serve as the Multiple System Atrophy (MSA) ’s distributors, traders, and dealers?
Q.6 How are market types and applications and deals, revenue, and value explored?
Q.7 What does a business area’s assessment of agreements, income, and value implicate?
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
About Author - Vaagisha Singh
Vaagisha brings over three years of expertise as a content editor in the market research domain. Originally a creative writer, she discovered her passion for editing, combining her flair for writing with a meticulous eye for detail. Her ability to craft and refine compelling content makes her an invaluable asset in delivering polished and engaging write-ups. LinkedIn